Ефективність застосування внутрішньовенного ізоніазиду та етамбутолу у хворих на туберкульозний менінгоенцефаліт

Abstract

Objective — study the effectiveness of i/v administration of isoniazid and ethambutol in patients with tuberculosis meningoencephalitis (TM). Materials and methods. We observed 54 patients was located TM aged 20 to 60 years. The patients were divided into the 1st and 2nd groups. 23 patients with TM who received i/v chemotherapy with isoniazid and ethambutol were assigned to the 1st group. Rifampicin and pyrazinamide were used in the 1st group per os . The 2nd group included 31 patients with TM who received chemotherapy with isoniazid, ethambutol, rifampicin, and pyrazinamide per os . Results and discussion. Positive X­ray dynamics of the chest was observed in 12 (52.1 %) patients in 1st group and 6 (19.3 %) in 2nd group (p 0.05) against the background of the corresponding clinical changes. In 1st group, 7 (30.4 %) patients died within the first two months, and 10 (32.2 %) in 2nd group (p > 0.05). Up to six months of treatment, another 2 (8.7 ± 6.0 %) patients with TM in 1st group and 12 (38.7 %) died in 2nd group (p < 0.05). Conclusions. Due to the i/v use of isoniazid and ethambutol in patients with TM, the main clinical manifestations of the disease were rapidly eliminated on the background of positive changes from the ­general analysis of blood and X­ray dynamics in the lungs compared with the oral administration of antituberculosis drugs. Conducting this chemotherapy reduces mortality of patients compared with the control group. I/v use of isoniazid and ethambutol in patients with TM does not cause additional side effects compared with the control group.